In this study we demonstrated that the CDK4/6 inhibitor abemaciclib alone or combined with osimertinib may be an effective strategy for NSCLC osimertinib-resistant patients progressed after either first- or second-line therapy. Here, CDK4 is linked to non-small cell lung carcinoma.